Effect of suprarenal versus infrarenal aortic endograft fixation on renal function and renal artery patency: a comparative study with intermediate follow-up  by Lau, L.Louis et al.
Effect of suprarenal versus infrarenal aortic
endograft fixation on renal function and renal
artery patency: A comparative study with
intermediate follow-up
L. Louis Lau, MD,a Albert G. Hakaim, MD,a W. Andrew Oldenburg, MD,a Beate Neuhauser, MD,a
J. Mark McKinney, MD,b Ricardo Paz-Fumagalli, MD,b and Andrew Stockland, MD,b Jacksonville, Fla
Purpose: Suprarenal fixation of aortic endografts appears to be a safe option in patients with a short or conical proximal
aortic neck. However, concern persists regarding the long-term effect on renal function when renal artery ostia are crossed
by the uncovered stent. We investigated the effect of suprarenal versus infrarenal endograft fixation on renal function and
renal artery patency after endovascular aortic aneurysm repair.
Methods: Records of 91 patients who underwent endovascular aortic aneurysm repair with a modular bifurcated stent graft
between November 1999 and January 2002 were reviewed retrospectively. Two patients receiving dialysis because of
chronic renal failure were excluded. Infrarenal fixation was used in 57 patients (group 1), and suprarenal fixation was used
in 32 patients (group 2). In two patients in group 1 a Gianturco Z stent was inserted transrenally because of
intraoperative proximal type I endoleak, and data for these patients were excluded from analysis. Follow-up evaluation
was performed at 1, 6, and 12 months, and yearly thereafter, and included clinical assessment, measurement of serum
creatinine concentration (SCr), and computed tomography angiography, per standard protocol. Median follow-up was
12 months (range, 1-36 months).
Results: There was no statistically significant difference in patient demographic data, aneurysm size, or preoperative risk
factors. Median SCr was significantly higher in group 2 (suprarenal fixation) than in group 1 (infrarenal fixation)
preoperatively (1.2 mg/dL [range, 0.6-2.3 mg/dL] vs 0.9 mg/dL [range, 0.6-1.9 mg/dL], P  .008) and at 1 month
postoperatively (1.1 mg/dL [range, 0.8-5.6 mg/dL] vs 1.0 mg/dL [range, 0.6-2.1 mg/dL], P  .045). There was a
significant increase in median SCr in both groups at 1 month postoperatively (group 1, 1.0 mg/dL [range, 0.6-2.1
mg/dL], P  .05; group 2, 1.1 mg/dL [range, 0.8-5.6 mg/dL] [mean SCr, 1.35 mg/dL vs 1.15 mg/dL, respectively],
P < .05). In group 1 SCr was increased significantly at 6 and 12 months (P < .001), whereas in group 2 SCr also increased
at 6 and 12 months, but not significantly. The change in SCr over time was not significantly different between the two
groups. In two of 32 patients in group 2, renal artery occlusion developed, associated with perfusion defects in renal
parenchyma and persistently elevated SCr. Analysis of renal artery patency did not demonstrate any association between
patency and treatment. No patient developed hypertension during follow-up.
Conclusions: Suprarenal endograft fixation does not lead to significant renal dysfunction, and renal artery occlusion is
uncommon within 12 months. A larger study with longer follow-up is essential to determine overall effects on renal
function and renal artery patency. (J Vasc Surg 2003;37:1162-8.)
Endovascular aneurysm repair (EVAR) is gaining wider
acceptance as a feasible alternative to conventional open
repair, especially in patients at high risk.1 Early results are
promising; however, there remains concern regarding
long-term durability compared with open repair.2 In addi-
tion, the optimum endograft design and mechanism of
aortic fixation remain to be determined, and a variety of
devices are still under investigation. Successful EVAR re-
quires secure fixation of the proximal end of the endograft
to prevent stent-graft migration and proximal endoleak.
Adverse morphologic features of the infrarenal aortic neck,
eg, severe angulation, short neck length, cone shape,
thrombus, or calcification, may adversely affect long-term
durability of this minimally invasive technique. With these
anatomic constraints, currently available commercial and
investigational devices allow as many as 60% of all infrarenal
abdominal aortic aneurysms (AAA) to be treated with
EVAR.3
To overcome the problem of unfavorable or subopti-
mal proximal neck, suprarenal endograft fixation has been
proposed as a more secure form of proximal fixation and to
increase the number of patients eligible for EVAR. Al-
though many authors have reported the effectiveness and
safety of suprarenal endograft fixation in studies with short-
term and intermediate follow-up,4-9 concern persists re-
garding the long-term effects on renal function and renal
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artery patency when the renal artery ostia are crossed by
struts of the uncovered stent. Various devices were used in
these studies, and the stent material used differed in con-
struction and configuration, which may variably affect renal
function and renal artery patency. We retrospectively eval-
uated our experience with suprarenal fixation of a single
type of endograft, compared with infrarenal fixation of a
single device, to determine its effect on renal function and
renal artery patency.
PATIENTS AND METHODS
The records of 91 consecutive patients who underwent
EVAR with a modular bifurcated endograft between No-
vember 1999 and January 2002 at our institution were
reviewed. Over the same period, 19 additional patients
underwent EVAR with an investigator-sponsored Investi-
gational Device Exemptions aorto-monoiliac device and 68
patients underwent conventional open repair. Endovascu-
lar repair was offered to patients who had suitable AAA
anatomy and were considered at high risk for open repair or
when the patient requested endografting. Two patients
receiving dialysis because of chronic renal failure before
EVAR were excluded. Fifty-seven patients (group 1) re-
ceived an endograft with infrarenal fixation (AneuRx;
Medtronic, Santa Rosa, Calif). In two patients in this group
a Gianturco Z stent was inserted to correct intraoperative
proximal type I endoleak, and data for these patients were
excluded from analysis; thus there were 55 patients in
group 1. Group 2 consisted of 32 patients who underwent
suprarenal endograft fixation with a Zenith stent graft
(Cook, Bloomington, Ind) (Fig 1) as part of a multicenter
phase II trial of the US Food and Drug Administration.
The two groups of patients received treatment within the
same period. Anatomic criteria were used to determine the
type of endograft to use. A proximal aortic neck diameter of
25 mm is not acceptable for the AneuRx endograft, and a
proximal neck diameter of 28 mm is acceptable for the
Zenith device. If the anatomy was suitable for both devices,
the option of either endograft was offered to patients. Some
patients preferred not to receive the study device because of
the associated extensive follow-up. All operations were
performed by two vascular surgeons (AGH and WAO),
who are proficient in EVAR. The study was approved by the
Mayo Foundation Institutional Review Board.
Baseline demographic data and preoperative risk fac-
tors, including hypertension, as defined by the Society for
Vascular Surgery/American Association for Vascular Sur-
gery reporting standard,10 were obtained for all patients.
Preoperative data recorded included aneurysm size and
morphologic features, serum creatinine concentration
(SCr), and obstructive renal artery disease documented
with computed tomography (CT) angiography with mul-
tiplanar reconstruction or duplex ultrasound (US) scan-
ning. Renal artery stenosis was further confirmed with
intraoperative angiography. All patients underwent a stan-
dardized surveillance protocol that included physical exam-
ination (including blood pressure measurements), SCr de-
termination, biplanar abdominal plain radiography, and CT
angiography at 1, 6, and 12 months and annually thereaf-
ter. All intraoperative completion arteriograms and postop-
erative CT angiograms were examined to identify any en-
doleaks, confirm patency of the stent graft and renal
arteries, and note presence of renal infarction. Duplex US
scanning and digital subtraction arteriography were per-
formed if additional information was needed or the CT scan
was inadequate. Duplex US scanning was performed by
certified vascular technicians using standardized criteria to
determine the presence of renal artery stenosis. A renal/
aortic peak systolic velocity (PSV) ratio3.5 and elevation
of renal artery PSV 200 cm/s constitute significant ste-
nosis, ie, 60%. Changes in antihypertensive therapy, in-
cluding angiotensin converting enzyme inhibitors, were
noted.
Statistical analysis. Data are expressed as median and
range. The Fisher exact test was used for comparison of
demographic data, preoperative risk factors, and renal ar-
tery patency between the two groups. Because SCr (mg/
dL) measurements in this cohort of patients were highly
skewed, nonparametric analysis was used as appropriate. A
repeated-measures analysis of variance model was also used
to analyze change in SCr over time within and between
groups. All tests were two-tailed, with P  .05 considered
significant.
RESULTS
Patient demographic data, aneurysm size, and preoper-
ative risk factors are listed in Table I. There was no signifi-
cant difference between the two groups. Median infrarenal
aortic neck length was 25 mm (range, 10-55 mm), and
interrenal aortic diameter 22 mm (range, 15-26 mm) in
group 1, compared with 25 mm (range, 15-65 mm) and 24
Fig 1. Zenith modular bifurcated endograft. Note suprarenal
uncovered stent crossing renal artery ostia.
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mm (18-27 mm), respectively, in group 2. Endograft de-
ployment was technically successful in all patients. There
were no intraoperative open conversion or perioperative
deaths. One patient in group 1 had previously undergone
nephrectomy because of renal cell carcinoma. Six patients
(three in each group) had a history of renal artery stenosis
and stent insertion before EVAR, but their SCr and blood
pressure were stable preoperatively. Four other patients
(two in each group) had unilateral significant renal artery
stenosis (50%) but normal preoperative SCr and blood
pressure. In one patient an attempt to stent the stenosed
renal artery during EVAR was unsuccessful. In one patient
in group 2 the right renal artery was inadvertently partially
covered by the graft fabric.
At median follow-up of 12 months (range, 1-36
months), hypertension had not developed in any patients,
and none required intensification of anti-hypertension
therapy. Seven patients underwent postoperative duplex
US scanning in addition to CT, because intravenous con-
trast material was not used because of renal insufficiency. In
the 6 patients with renal artery stenosis with a stent inserted
before EVAR, neither significant change in SCr nor renal
artery disease progression was noted during follow-up. In
group 1 (infrarenal fixation), there were 126 renal arteries
in 55 patients. No patients had main renal artery occlusion
(Table II). In two patients an accessory renal artery was
covered intentionally, and follow-up CT scans showed
renal polar atrophy but no significant change in postoper-
ative SCr. The two patients with preoperatively stenosed
renal arteries (50%) showed no progression of stenosis
during follow-up.
In group 2 (suprarenal fixation), there were 71 renal
arteries in 32 patients. In the two patients with asymptom-
atic renal artery stenosis preoperatively, renal artery occlu-
sion associated with renal atrophy was demonstrated on
contrast-enhanced CT scans at 1-month follow-up (Fig 2),
and SCr was persistently elevated compared with preoper-
ative concentration, from 1.3 mg/dL to 1.8 mg/dL, and
1.3 mg/dL to 2.1 mg/dL, respectively. In the patient with
the right renal artery inadvertently covered by a malposi-
Table I. Patient demographic data and preoperative risk
factors
Group 1
(n  55)
Group 2
(n  32)
n % n %
Age (y)
Median 75 77
Range 53-88 62-88
Sex (M/F) 51/4 27/5
AAA diameter (mm)
Median 55 54
Range 42-84 46-82
Smoker 8 15 5 16
Coronary artery disease 27 49 17 53
Hypertension 34 62 23 72
Diabetes mellitus 3 5 4 13
Hypercholesterolemia 26 47 14 44
Renal artery stent 3 5 3 9
Untreated renal artery stenosis
(50%)
2 4 2 6
ACE inhibitors therapy 16 29 7 22
Previous nephrectomy 1 2 0
AAA, Abdominal aortic aneurysm; ACE, angiotensin converting enzymes.
Table II. Renal artery patency at end of study (P  .127,
Fisher’s exact tests)
Group 1
(n  55)
Group 2
(n  32)
Patent renal artery* 126 68
Occluded renal artery 0 2†
Total 126 70
*P  .127 (Fisher exact test), group 1 vs group 2.
†These two arteries had 50% stenosis preoperatively.
Fig 2. Axial contrast-enhanced CT scans of one of two patients
with preexisting renal artery stenosis. A, Scan obtained before
EVAR shows patent renal arteries and contrast uptake by kidneys.
B, Scan obtained 1 month after endografting. Left kidney is
atrophic, with nonfilling of the left renal artery compared with
normal sized right kidney with widely patent right renal artery.
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tioned stent graft, SCR irreversibly increased, from 0.9
mg/dL to 1.7 mg/dL. Follow-up CT scans and duplex US
scans confirmed an atrophic right kidney and nonfilling of
the right renal artery. In another patient in group 2, a left
accessory renal artery was covered intentionally, and SCr
was transiently elevated. CT scans confirmed a small upper
pole infarct, but the main renal arteries remained patent.
Excluding the inadvertently covered renal artery, analysis of
renal artery patency did not demonstrate any association
between patency and type of endograft fixation (P  .127,
Fisher exact test).
Median SCr was significantly higher in group 2 (supra-
renal) versus group 1 (infrarenal) preoperatively (1.2
mg/dL [range, 0.6-2.3 mg/dL] vs 0.9 mg/dL [range,
0.6-1.9 mg/dL]; P .008) and at 1 month postoperatively
(1.1 mg/dL [range, 0.8-5.6 mg/dL] vs 1.0 mg/dL
[range, 0.6-2.1 mg/dL]; P  .045) (Fig 3). In group 1
there was a significant increase in median SCr at 1 month (P
 .05), 6 months (P  .001), and 12 months (P  .001),
compared with preoperative levels. In group 2 there was a
small but significant increase in SCr at 1 month (1.1
mg/dL [range, 0.8-5.6 mg/dL]; P  .035). Although
median SCr was lower than the preoperative value, a larger
proportion of patients (47%) had increased SCr, as com-
pared with 31% of patients with decreased SCr, and the
magnitude of the increases was greater than the decreases,
hence an overall significant increase in SCr at 1 month
(mean SCr, 1.35 mg/dL vs 1.15 mg/dL). However, this
increase was small, and the evidence was not overwhelming.
At 6 and 12 months, there was no statistically significant
increase in SCr (1.2 mg/dL [range, 0.8-2.1 mg/dL], P 
.29, and 1.3 mg/dL [range, 0.7-3.2 mg/dL], P  .07,
respectively). If the two patients with preexisting renal
artery stenosis with subsequent occlusion and the patient
with inadvertent renal artery coverage were excluded from
the analysis, median SCr did not change significantly after
EVAR in group 2. With repeated-measures analysis of
variance model, change in SCr over time was not signifi-
cantly different between the two groups during the study
period (P  .408).
During follow-up there were 11 endoleaks (two type I,
nine type II) in group 1 and nine in group 2 (all type II). In
one patient in group 1 the stent graft migrated; endovas-
cular intervention failed, and late open conversion was
necessary. Another patient underwent late open conversion
because of endotension and increasing aneurysm size. In
one patient in group 2 a suprarenal aneurysm developed
adjacent to the suprarenal bare stent of the endograft and
required open repair. Another patient had a myocardial
infarction shortly after EVAR, and acute chronic renal
failure developed, which improved with medical treatment
without the need for dialysis. SCr increased from 2.3
mg/dL preoperatively to 5.6 mg/dL at 1 month.
DISCUSSION
Unfavorable anatomy of the proximal aortic neck is one
of the most common causes of patient exclusion from
EVAR. Anchoring the endograft in the undilated suprare-
nal aorta with an uncovered stent to improve proximal
fixation may extend the indication for EVAR to include this
subgroup of patients. Earlier studies support the renal
safety of suprarenal endograft fixation4-8 (Table III). How-
ever, long-term safety associated with placing an uncovered
stent across the renal artery ostia remains a major concern.
Malina et al4 reported 18 patients with suprarenal
fixation of a Gianturco Z stent graft with median follow-up
of 6 months. Using CT, angiography, and SCr measure-
ment, they found no evidence of renal artery compromise
or deterioration of renal function, but CT scans did show a
small infarct in one kidney. Marin et al5 compared findings
in 37 patients with suprarenal endograft fixation with those
in 16 patients with infrarenal fixation of a homemade
endograft constructed from a Palmaz balloon-expandable
stent and an expandable polytetrafluoroethylene graft. At
mean follow-up of 10 months there was no significant
change in SCr or hypertension status in these patients.
Angiograms, CT scans, and duplex US scans did not show
significant renal artery compromise when the endograft was
properly placed. In two patients follow-up CT scans dem-
onstrated segmental renal artery infarction but no change
in renal function. Lobato et al6 studied 35 patients who
underwent EVAR with suprarenal fixation with three types
of endograft. At median follow-up of 11 months, 14% of
patients had transiently elevated SCr after endografting,
but there was no significant difference between preproce-
dural and postprocedural SCr. Bove et al7 reported 28
patients with suprarenal endograft fixation with median
follow-up of 6 months. Five patients with elevated preop-
erative SCr had persistent elevation postoperatively, and
three had a greater than 20% increase from preoperative
levels. One patient with normal preoperative renal function
had persistently elevated SCr postoperatively. No localized
Fig 3. Box and whisker plot of serum creatinine concentration. *P
 .045, †P  .008, group 1 vs group 2. Open circles, Extreme
values; open boxes, group 1 (infrarenal fixation); solid boxes, group 2
(suprarenal fixation).
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perfusion defect was identified in the renal parenchyma at
duplex US scanning or CT angiography. Kichikawa et al8
evaluated their experience with use of a newly designed
spiral Z stent endograft with suprarenal fixation in 18
patients with mean follow-up of 14 months. Renal function
and renal artery patency were affected in only one patient,
in whom bilateral renal artery stenosis developed after
endografting and was treated with bilateral renal stenting.
More recently, Kramer et al9 reviewed 99 patients with
more than 12 months of follow-up after EVAR with seven
types of endograft. They concluded that there was no
significant difference in incidence of renal infarction relative
to suprarenal or infrarenal endograft fixation. In a larger
series, Burks et al11 reviewed 192 patients who underwent
suprarenal endograft fixation with two types of endograft
with mean follow-up of 25 months. Follow-up CT angio-
grams showed no evidence of stenosis, occlusion, or throm-
boembolism within the visceral arteries. Median SCr was
not significantly changed after endografting. In another
large series, Abraham et al12 reported 116 patients who
received the Zenith device. Renal artery stenosis and occlu-
sion developed in only one patient, 6 months after en-
dografting, which they attributed to impingement of the
proximal edge of the graft on the renal orifices.
These studies suggest that suprarenal endograft fixa-
tion is benign, and the results of our study appear to
corroborate this observation. With repeated measures of
analysis of variance, we found no significant difference in
the change over time in SCr during the 12 months of
follow-up between suprarenal and infrarenal endograft fix-
ation. Of the 87 patients included in the analysis, 13
patients (15%) had preoperative SCr 1.3 g/dL. The
suprarenal group had higher preoperative SCr, but this
simply reflects the nonrandomized nature of the study.
Over the study period, SCr increased in both groups of
patients, although it did not reach statistical significance in
the suprarenal group. The infrarenal group demonstrated a
significant increase in SCr, but the increases were small, and
clinically, median SCr was within the normal range. This is
comparable to findings of Carpenter et al,13 who reported a
20% incidence of baseline renal insufficiency in patients
undergoing EVAR. In 24% of their patients SCr increased
above baseline after endografting, independent of use of
infrarenal or suprarenal fixation. Many factors may be re-
sponsible for the increase in SCr after endografting. Con-
trast-induced renal insufficiency has been well docu-
mented, and repeated use during follow-up may contribute
to increased SCr.13 Patients with preexisting renal insuffi-
ciency are at particular risk, and alternative follow-up im-
aging techniques or strategies for reducing adverse renal
events should be considered in this group of patients.
Thromboembolism during endografting may also be a
contributing factor to renal impairment. A small amount of
thrombus in the aortic neck might be present and not
detected at preoperative imaging. Manipulation of the en-
dograft within the aortic neck and aneurysm sac, balloon
expansion of the proximal stent, or maneuvers in reposi-
tioning of the endograft may result in embolism or throm-
bosis of the renal arteries. Findings of punctate renal infarc-
tions on follow-up CT scans have been noted in various
studies, suggesting atheroembolic sequelae of EVAR.9
The two patients in our series in whom renal artery
occlusion developed had preexisting renal artery stenosis
50%. Whether occlusion was a result of the struts of the
uncovered stent crossing the renal artery ostia or due to
progression of the atherosclerotic disease per se is difficult
to determine. Results from earlier studies are inconclusive.
In the study by Marin et al,5 18 patients with preexisting
significant renal artery stenosis underwent suprarenal en-
dograft fixation and did not demonstrate any disease pro-
gression. In contrast, Lobato et al6 reported that in one of
five patients with preexisting unilateral renal artery stenosis
60% the disease progressed to 99% stenosis at 4 months
after suprarenal fixation. Similarly, Bove et al7 reported that
one of eight patients with preoperative evidence of renal
artery atherosclerotic disease had progression of renal artery
stenosis from 30% to 60% 12 months after endografting. In
another patient with normal renal artery preoperatively,
stenosis 60% had developed at 1-month follow-up. Al-
though stenosis progression may be due to the natural
Table III. Summary of published series of patients with suprarenal endograft fixation
Author Year
No. of
patients Endograft used
Follow-up
(mo)
Postoperative renal artery stenosis,
occlusion, or infarction
Increase in
postoperative SCr
Malina et al4 1997 18 Homemade (Gianturco Z/
dacron)
Median, 6 1 Partial renal infarction No
Marin et al5 1998 37 Homemade (Palmaz/ePTFE) Mean, 10 2 Arteries inadvertently covered No
Labato et al6 2000 35 Talent, Vanguard, Homemade
(Gianturco Z/eTPFE)
Median, 11 1 Artery stenosis 5 (Transient)
Bove et al7 2000 28 Talent Median, 6 6 Artery stenosis 4 (Persistent)
Kichikawa et al8 2000 18 Homemade (Spiral Z stent/
dacron)
Mean, 14 1 Artery stenosis 1 (Persistent)
Kramer et al9 2002 66 Talent, Vanguard, Zenith 12 6 Partial renal infarctions NA
Burks et al10 2002 192 Talent, homemade (Palmaz/
ePTFE)
Mean, 25 2 Arteries inadvertently covered No
Abraham et al11 2002 116 Zenith 1-34 1 Artery occlusion 1 (Renal failure)
ePTFE, Expanded polytetrafluoroethylene; SCr, serum creatinine concentration; NA, data not available.
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history of the renal artery disease, it is possible that the
suprarenal stent may have accelerated the disease progres-
sion, because renal blood flow must be maintained via stent
interstices. The numbers of patients affected in these series,
including the current study, were small, and no conclusion
can be drawn regarding the possible role of suprarenal
fixation on progression of renal atherosclerotic disease.
Whether these lesions should be treated preoperatively or
during EVAR needs further study.
Another factor that may have an important influence on
renal artery patency is the type of stent used for proximal
fixation. In a porcine model, Birch et al14 demonstrated
that development of disorganized acellular matrix causing
partial renal ostial occlusion depends on stent type. A
variety of stents were used for proximal fixation in clinical
studies, which may account for the difference observed in
renal artery patency. Conclusions drawn from the data in
these studies should be interpreted with caution.
In the current study, SCr measurement was used to
determine functional status of the kidneys after EVAR. We
admit this is not a sensitive method for detecting renal
dysfunction. Significant renal parenchymal tissue loss or
renal artery stenosis can occur without a significant effect
on SCr. Measurement of creatinine clearance may provide
more useful information regarding functional status of the
kidneys, but it was not part of our surveillance protocol.
Nevertheless, we retrospectively estimated creatinine clear-
ance preoperatively and at 12 months post-EVAR in the
two groups of patients with the Cockcroft-Gault formu-
la.15 There was no significant difference in change in creat-
inine clearance over the 12 months between the two groups
(P .121), consistent with SCr results (Fig 4). In addition,
angiography and contrast- enhanced CT may not be ideal
methods for evaluation of renal artery anatomy and patency
after EVAR. Intrarenal color duplex US scanning has been
suggested as a simple and affordable screening tool, but it is
operator-dependent and technically difficult.16 Intravascu-
lar US is a more reliable and accurate method for assessing
the renal arteries, but it is more invasive and not practical as
a surveillance tool. Magnetic resonance angiography has
been used to diagnose renal artery stenosis, but its safety in
patients with endografts is unknown.17 Further studies are
required to determine the ideal surveillance tool for renal
artery luminal configuration and renal circulation in pa-
tients with suprarenal endograft fixation.
In conclusion, our experience with suprarenal en-
dograft fixation with the Zenith device, based on interme-
diate follow-up, suggests that renal dysfunction and renal
artery occlusion are uncommon in patients with no preex-
isting significant renal artery stenosis. However, it should
be noted that this is a retrospective cohort study of a single
institutional experience and that the number of patients in
the suprarenal group was relatively small. Although we
found no significant effect of suprarenal stenting on post-
operative renal function and renal artery patency, renal
artery occlusion occurred in the two patients who had
preexisting renal artery stenosis in the suprarenal group. It
is advisable to exercise caution when suprarenal endograft
fixation is considered in these patients. A larger study with
longer follow-up is necessary to assess the overall effects of
various endografts on renal artery patency and renal func-
tion, especially in the subgroup of patients with significant
renal atherosclerotic disease.
We thank Stephen Weigand, MS, and Peter O’Brien,
PhD, for help with statistical analysis.
Fig 4. Estimated creatinine clearance, Cockcroft-Gault formula. P .121, Wilcoxon rank-sum test, group 1 vs group
2. Open boxes, Group 1 (infrarenal fixation); solid boxes, group 2 (suprarenal fixation). Creatinine clearance  [(140 
age)  weight]/(SCr  72) for men or [(140  age)  weight]/(SCr  85) for women.
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